

September 9, 2016

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Norio Hamada, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Corporate Officer, Joint General Manager, Corporate Planning Division and General Manager, Public and Investor Relations Office (TEL: 03-6838-2803)

Notice Regarding Share Acquisition of MCOM Kyushu

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) is pleased to announce that it has decided to acquire all outstanding shares of MCOM Kyushu CO., LTD. (Headquarters: Fukuoka; President and Representative Director: Yoshihiko Miisyo; hereinafter, “MCOM Kyushu”) engaged in the pharmaceutical wholesaling business in the Kyushu area.

1. Purpose of the Share Acquisition

As a group of distribution companies engaged in the medical, health and nursing care sector and under the group’s corporate slogan, “Total commitment to good health”, TOHO HOLDINGS conducts businesses such as pharmaceutical wholesaling, management of dispensing pharmacies, development and provision of customer support systems, etc., and at the same time, actively promotes community healthcare collaboration and makes positive commitments to the home medical and nursing care sector.

MCOM Kyushu is a pharmaceutical wholesale company based mainly in Fukuoka, Saga and Nagasaki Prefectures. TOHO HOLDINGS acquired 40% of its outstanding shares on April 25, 2014.

TOHO HOLDINGS has decided to make MCOM Kyushu a wholly-owned subsidiary by acquiring the remaining 60% of its outstanding shares, with a view to boosting our corporate value, by further strengthening ties between the two companies from this point onward, and stepping up our sales capabilities in the above-mentioned regions.

2. Schedule

Conclusion of agreement on the stock transfer	October 3, 2016 (planned)
Proposed effective date	2017 January (planned)

3. Performance outlook

There will be little influence on its consolidated financial results in FY ending March 2017.

